Entering text into the input field will update the search result below

Eli Lilly wins FDA accelerated approval for lymphoma therapy

Jan. 27, 2023 2:42 PM ETEli Lilly and Company (LLY) StockBy: Dulan Lokuwithana, SA News Editor2 Comments

Eli Lilly and Company Research Laboratories. Lilly makes Medicines and Pharmaceuticals.

jetcityimage/iStock Editorial via Getty Images

The oncology division of Eli Lilly (NYSE:LLY) announced Friday that the FDA greenlighted its Bruton's tyrosine kinase (BTK) inhibitor Jaypirca as a late-line option for certain patients with mantle cell lymphoma (MCL), a rare blood cancer.

Recommended For You

About LLY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LLY--
Eli Lilly and Company